natgillin/translations-raw huggingface dataset:
The coordinator and the other relevant competent authorities shall agree on the form and content of the significant risk concentration report, including language, remittance dates and channels of communication.
Koordinator in drugi ustrezni pristojni organi se dogovorijo o obliki in vsebini poročila o pomembni koncentraciji tveganja, vključno z jezikom, datumi predložitve in načini komunikacije.
The coordinator and the other relevant competent authorities shall at least require regulated entities or mixed financial holding companies to report the following:
Koordinator in drugi ustrezni pristojni organi zahtevajo, da regulirane osebe ali mešani finančni holdingi poročajo vsaj naslednje:
a description of the significant risk concentration according to the types of risks set out in paragraph 1;
opis pomembne koncentracije tveganja glede na vrste tveganj, določene v odstavku 1;
the break-down of the significant risk concentration by counterparties and groups of interconnected counterparties, geographical areas, economic sectors, currencies, identifying the names, company register numbers or other identification numbers of the relevant group companies of the financial conglomerate and their respective counterparties, including LEI, where applicable;
razčlenitev pomembne koncentracije tveganja po nasprotnih strankah in skupinah medsebojno povezanih nasprotnih strank, geografskih območjih, gospodarskih sektorjih in valutah z navedbo imen, številk v poslovnem registru ali drugih identifikacijskih številk zadevne skupine podjetij v finančnem konglomeratu in njihovih zadevnih nasprotnih strank, vključno z LEI, kjer je to ustrezno;
the total amount of each significant risk concentration at the end of a specific reporting period valued according to the applicable sectoral rules;
skupni znesek vsake pomembne koncentracije tveganja ob koncu posameznega obdobja poročanja, ovrednoten v skladu z veljavnimi sektorskimi pravili;
if applicable, the amount of significant risk concentration taking into account risk mitigation techniques and risk weighting factors;
če je ustrezno, znesek pomembne koncentracije tveganja ob upoštevanju tehnik zmanjševanja tveganja in faktorjev uteži tveganja;
information on how conflicts of interests and risks of contagion at the level of the financial conglomerate regarding significant risk concentration are managed, taking into consideration the financial conglomerate's strategy to combine activities in the banking, insurance and investment services sectors, or a sectoral own risks self-assessment including a consideration on the management of conflicts of interests and risks of contagion regarding significant risk concentration.
informacije o načinu obvladovanja nasprotij interesov in tveganja širjenja negativnih vplivov na ravni finančnega konglomerata v zvezi s koncentracijo tveganja, pri čemer upoštevajo strategijo finančnega konglomerata za združevanje dejavnosti v sektorjih bančnih, zavarovalniških in investicijskih storitev ali sektorsko samooceno lastnih tveganj, vključno z upoštevanjem obvladovanja nasprotij interesov in tveganj širjenja negativnih vplivov v zvezi s koncentracijo tveganja.
Supervisory measures
Nadzorni ukrepi
Without prejudice to any other supervisory powers conferred on them, competent authorities shall, in particular,
Brez poseganja v katera koli druga nadzorna pooblastila, ki so jim bila podeljena pristojni organi, zlasti:
require, where appropriate, regulated entities or mixed financial holding companies to:
zahtevajo, kjer je to primerno, da regulirane osebe ali mešani finančni holdingi:
perform intra-group transactions of the financial conglomerate at arm's length or notify intra-group transactions which are not performed at arm's length;
opravljajo posle v skupini finančnega konglomerata po običajnih tržnih pogojih oziroma sporočijo posle v skupini, ki se ne opravijo po običajnih tržnih pogojih;
approve intra-group transactions of the financial conglomerate through specified internal procedures with the involvement of its management body as referred to in Article 3(1) of Directive 2013/36/EU of the European Parliament and of the Council [5], or of its administrative, management or supervisory body as referred to in Article 40 of Directive 2009/138/EC of the European Parliament and of the Council [6];
odobrijo posle v skupini finančnega konglomerata s posebnimi notranjimi postopki, v katere je vključen njegov upravni organ, kakor je navedeno v členu 3(1) Direktive 2013/36/EU Evropskega parlamenta in Sveta [5], ali njegov upravni, poslovodni ali nadzorni organ, kakor je navedeno v členu 40 Direktive 2009/138/ES Evropskega parlamenta in Sveta [6];
report more frequently than required under Article 7(2) and Article 8(2) of Directive 2002/87/EC on significant risk concentration and significant intra-group transactions;
pogosteje, kot to zahtevata člen 7(2) in člen 8(2) Direktive 2002/87/ES, poročajo o pomembni koncentraciji tveganja in pomembnih poslih v skupini;
establish additional reporting on significant risk concentration and significant intra-group transactions of the financial conglomerate;
vzpostavijo dodatno poročanje o pomembni koncentraciji tveganja in pomembnih poslih v skupini finančnega konglomerata;
strengthen the risk management processes and internal control mechanisms of the financial conglomerate;
okrepijo postopke obvladovanja tveganja in mehanizme notranjega nadzora finančnega konglomerata;
present or improve plans to restore compliance with supervisory requirements and to set a deadline for implementation thereof;
predložijo ali izboljšajo načrte za ponovno zagotovitev skladnosti z nadzornimi zahtevami in določijo rok za njihovo izvajanje;
shall define appropriate thresholds in order to identify and overview significant risk concentration and significant intra-group transactions;
določijo ustrezne pragove za prepoznavanje in spremljanje pomembne koncentracije tveganja in pomembnih poslov v skupini.
Regulation (EU) No 1093/2010 of the European Parliament and of the Council of 24 November 2010 establishing a European Supervisory Authority (European Banking Authority), amending Decision No 716/2009/EC and repealing Commission Decision 2009/78/EC (OJ L 331, 15.12.2010, p. 12).
Uredba (EU) št. 1093/2010 Evropskega parlamenta in Sveta z dne 24. novembra 2010 o ustanovitvi Evropskega nadzornega organa (Evropski bančni organ) in o spremembi Sklepa št. 716/2009/ES ter razveljavitvi Sklepa Komisije 2009/78/ES (UL L 331, 15.12.2010, str. 12).
Regulation (EU) No 1095/2010 of the European Parliament and of the Council of 24 November 2010 establishing a European Supervisory Authority (European Securities and Markets Authority), amending Decision No 716/2009/EC and repealing Commission Decision 2009/77/EC (OJ L 331, 15.12.2010, p.
Uredba (EU) št. 1095/2010 Evropskega parlamenta in Sveta z dne 24. novembra 2010 o ustanovitvi Evropskega nadzornega organa (Evropski organ za vrednostne papirje in trge) in o spremembi Sklepa št. 716/2009/ES ter razveljavitvi Sklepa Komisije 2009/77/ES (UL L 331, 15.12.2010, str. 84).
84).
Direktiva 2013/36/EU Evropskega parlamenta in Sveta z dne 26. junija 2013 o dostopu do dejavnosti kreditnih institucij in bonitetnem nadzoru kreditnih institucij in investicijskih podjetij, spremembi Direktive 2002/87/ES in razveljavitvi direktiv 2006/48/ES in 2006/49/ES (UL L 176, 27.6.2013, str. 338).
Directive 2013/36/EU of the European Parliament and of the Council of 26 June 2013 on access to the activity of credit institutions and the prudential supervision of credit institutions and investment firms, amending Directive 2002/87/EC and repealing Directives 2006/48/EC and 2006/49/EC (OJ L 176, 27.6.2013, p. 338).
Direktiva 2009/138/ES Evropskega parlamenta in Sveta z dne 25. novembra 2009 o začetku opravljanja in opravljanju dejavnosti zavarovanja in pozavarovanja (Solventnost II) (UL L 335, 17.12.2009, str. 1).
Commission Implementing Regulation (EU) 2015/2304
Izvedbena uredba Komisije (EU) 2015/2304
concerning the authorisation of a preparation of endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase produced by Talaromyces versatilis sp. nov.
o izdaji dovoljenja za pripravek iz endo-1,4-beta-ksilanaze in endo-1,3(4)-beta-glukanaze, ki ju proizvajata Talaromyces versatilis sp. nov. IMI CC 378536 in Talaromyces versatilis sp. nov. DSM 26702, kot krmni dodatek za purane za pitanje in razplod (imetnik dovoljenja Adisseo France S.A.S.)
IMI CC 378536 and Talaromyces versatilis sp. nov DSM 26702 as a feed additive for turkeys for fattening and for breeding (holder of the authorisation Adisseo France S.A.S.)
(Besedilo velja za EGP)
THE EUROPEAN COMMISSION,
ob upoštevanju Uredbe Evropskega parlamenta in Sveta (ES) št. 1831/2003 z dne 22. septembra 2003 o dodatkih za uporabo v prehrani živali [1] in zlasti člena 9(2) Uredbe,
Whereas:
Uredba (ES) št. 1831/2003 določa izdajo dovoljenj za dodatke za uporabo v prehrani živali ter razloge in postopke za izdajo takih dovoljenj.
Regulation (EC) No 1831/2003 provides for the authorisation of additives for use in animal nutrition and for the grounds and procedures for granting such authorisation.
V skladu s členom 7 Uredbe (ES) št. 1831/2003 je bil vložen zahtevek za izdajo dovoljenja za pripravek iz endo-1,4-beta-ksilanaze EC 3.2.1.8 in endo-1,3(4)-beta-glukanaze EC 3.2.1.6, ki ju proizvajata Talaromyces versatilis sp. nov. IMI CC 378536 in Talaromyces versatilis sp. nov. DSM 26702.
In accordance with Article 7 of Regulation (EC) No 1831/2003 an application was submitted for the authorisation of a preparation of endo-1,4-beta-xylanase EC 3.2.1.8 and endo-1,3(4)-beta-glucanase EC 3.2.1.6 produced by Talaromyces versatilis sp. nov.
V skladu s členom 7(3) navedene uredbe so bili navedenemu zahtevku priloženi zahtevani podatki in dokumenti.
IMI CC 378536 and Talaromyces versatilis sp. nov.
Navedeni zahtevek zadeva dovoljenje za pripravek iz endo-1,4-beta-ksilanaze EC 3.2.1.8 in endo-1,3(4)-beta-glukanaze EC 3.2.1.6, ki ju proizvajata Talaromyces versatilis IMI CC 378536 in Talaromyces versatilis sp. nov. DSM 26702, kot krmni dodatek za vse večje in manjše vrste perutnine za pitanje, nesenje jajc in razplod ter njegovo uvrstitev v kategorijo dodatkov „zootehnični dodatki“.
DSM 26702.
Uporaba navedenega pripravka je bila z Izvedbeno uredbo Komisije (EU) 2015/661 [2] za deset let odobrena za piščance za pitanje, piščance za nesenje jajc in manjše vrste perutnine za pitanje in nesenje jajc.
That application was accompanied by the particulars and documents required under Article 7(3) of that Regulation.
Evropska agencija za varnost hrane (v nadaljnjem besedilu: Agencija) je v svojem mnenju z dne 28. aprila 2015 [3] navedla, da pripravek iz endo-1,4-beta-ksilanaze EC 3.2.1.8 in endo-1,3(4)-beta-glukanaze EC 3.2.1.6, ki ju proizvajata Talaromyces versatilis IMI CC 378536 in Talaromyces versatilis sp. nov. DSM 26702, pod predlaganimi pogoji uporabe nima škodljivega učinka na zdravje živali in ljudi ali na okolje ter da znatno izboljša prirast teže pri puranih za pitanje.
That application concerns the authorisation of the preparation of endo-1,4-beta-xylanase EC 3.2.1.8 and endo-1,3(4)-beta-glucanase EC 3.2.1.6 produced by Talaromyces versatilis IMI CC 378536 and Talaromyces versatilis sp. nov.
Ta ugotovitev se razširi na purane za razplod.
DSM 26702 as a feed additive for all major and minor poultry species for fattening, reared for laying and breeding, to be classified in the additive category ‘zootechnical additives’.
Agencija meni, da ni potrebe po posebnih zahtevah v zvezi s spremljanjem po dajanju na trg.
The use of that preparation was authorised for 10 years for chickens for fattening, chickens reared for laying and minor poultry species for fattening and reared for laying by Commission Implementing Regulation (EU) 2015/661 [2].
Potrdila je tudi poročilo o analitski metodi krmnega dodatka, ki ga je predložil referenčni laboratorij, ustanovljen z Uredbo (ES) št. 1831/2003.
The European Food Safety Authority (‘the Authority’) concluded in its opinion of 28 April 2015 [3] that, under the proposed conditions of use, the preparation of endo-1,4-beta-xylanase EC 3.2.1.8 and endo-1,3(4)-beta-glucanase EC 3.2.1.6 produced by Talaromyces versatilis IMI CC 378536 and Talaromyces versatilis sp. nov.
Ocena pripravka iz endo-1,4-beta-ksilanaze in endo-1,3(4)-beta-glukanaze je pokazala, da so pogoji za dovoljenje iz člena 5 Uredbe (ES) št. 1831/2003 izpolnjeni.
DSM 26702 does not have an adverse effect on animal health, human health or the environment, and that it has a significant improvement in the feed-to-gain ratio of turkeys for fattening.
Zato bi bilo treba dovoliti uporabo navedenega pripravka, kakor je opredeljeno v Prilogi k tej uredbi.
This conclusion is extended to turkeys reared for breeding.
Ukrepi iz te uredbe so v skladu z mnenjem Stalnega odbora za rastline, živali, hrano in krmo –
The assessment of the preparation of endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied.
Pripravek iz Priloge, ki spada v kategorijo dodatkov „zootehnični dodatki“ in funkcionalno skupino „pospeševalci prebavljivosti“, se odobri kot dodatek v prehrani živali v skladu s pogoji iz navedene priloge.
Article 1
V Bruslju, 10. decembra 2015
The preparation specified in the Annex, belonging to the additive category ‘zootechnical additives’ and to the functional group ‘digestibility enhancers’, is authorised as an additive in animal nutrition, subject to the conditions laid down in that Annex.
Za Komisijo
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
UL L 268, 18.10.2003, str. 29.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
Izvedbena uredba Komisije (EU) 2015/661 z dne 28. aprila 2015 o izdaji dovoljenja za pripravek iz endo-1,4-beta-ksilanaze in endo-1,3(4)-beta-glukanaze, ki ju proizvajata Talaromyces versatilis sp. nov. IMI CC 378536 in Talaromyces versatilis sp. nov. DSM 26702., kot krmni dodatek za piščance za pitanje, piščance za nesnice in manjše vrste perutnine za pitanje in za nesnice (imetnik dovoljenja Adisseo France S.A.S.)
Done at Brussels, 10 December 2015.
(UL L 110, 29.4.2015, str. 1).
For the Commission
EFSA Journal (2014); 13(5):4106.
OJ L 268, 18.10.2003, p. 29.
Identifikacijska številka dodatka
Commission Implementing Regulation (EU) 2015/661 of 28 April 2015 concerning the authorisation of the preparation of endo-1,4-beta-xylanase and endo-1,3(4)-beta-glucanase produced by Talaromyces versatilis sp. nov.
Ime imetnika dovoljenja
IMI CC 378536 and Talaromyces versatilis sp. nov.
Dodatek
DSM 26702. as a feed additive for chickens for fattening, chickens reared for laying and minor poultry species for fattening and reared for laying (holder of the authorisation Adisseo France S.A.S.)
Sestava, kemijska formula, opis, analitska metoda
(OJ L 110, 29.4.2015, p. 1).
Vrsta ali kategorija živali
EFSA Journal 2014; 13(5):4106.
Najvišja starost
ANNEX
Najnižja vsebnost
Identification number of the additive
Najvišja vsebnost
Name of the holder of authorisation
Druge določbe
Additive
Datum poteka veljavnosti dovoljenja
Composition, chemical formula, description, analytical method
Enote aktivnosti/kg popolne krmne mešanice z vsebnostjo vlage 12 %
Species or category of animal
Kategorija zootehničnih dodatkov.
Maximum age
Funkcionalna skupina: pospeševalci prebavljivosti
Minimum content
endo-1,4-beta-ksilanaza EC 3.2.1.8
Maximum content
endo-1,3(4)-beta-glukanaza EC 3.2.1.6
Other provisions
Sestava dodatka
End of period of authorisation
Pripravek iz endo-1,4-beta-ksilanaze (EC 3.2.1.8) in endo-1,3(4)-beta-glukanaze (EC 3.2.1.6), ki ju proizvajata Talaromyces versatilis sp. nov. IMI CC 378536 in Talaromyces versatilis sp.nov.
Units of activity/kg of complete feedingstuff with a moisture content of 12 %
DSM 26702, z najmanjšo aktivnostjo:
Functional group: digestibility enhancers
v tekoči obliki: aktivnost endo-1,4-beta-ksilanaze 5500 EV/ml in endo-1,3(4)-beta-glukanaze 3800 EV/ml.
Endo-1,3(4)-beta-glucanase EC 3.2.1.6
Endo-1,4-beta-ksilanaza (EC 3.2.1.8) in endo-1,3(4)-beta-glukanaza (EC 3.2.1.6), ki ju proizvajata Talaromyces versatilis sp. nov. IMI CC 378536 in Talaromyces versatilis sp. nov. DSM 26702.
solid form: endo-1,4-beta-xylanase 22000 VU [1]/g and endo-1,3(4)-beta-glucanase 15200 VU/g;
purani za pitanje
liquid form: endo-1,4-beta-xylanase activity of 5500 VU/ml and endo-1,3(4)-beta-glucanase 3800 VU/ml.
purani za razplod
Characterisation of the active substance
endo-1,4-beta-ksilanaza 1100 EV
Endo-1,4-beta-xylanase (EC 3.2.1.8) and endo-1,3(4)-beta-glucanase (EC 3.2.1.6) produced by Talaromyces versatilis sp. nov.
endo-1,3(4)-beta-glukanaza 760 EV
IMI CC 378536 and Talaromyces versatilis sp. nov.
V navodilih za uporabo dodatka in premiksa je treba navesti pogoje skladiščenja in obstojnost pri peletiranju.
DSM 26702.
Zaradi varnosti je treba pri ravnanju z dodatkom uporabljati zaščito za dihala, zaščitna očala in rokavice.
Analytical method [2]For the quantification of endo-1,4-beta-xylanase activity:
31. december 2025
viscosimetric method based on decrease in viscosity produced by action of endo-1,3(4)-beta-glucanase on the glucan substrate barley betaglucan at pH = 5,5 and 30 °C.
Adisseo France SAS
Commission Implementing Regulation (EU) 2015/2305
Izvedbena uredba Komisije (EU) 2015/2305
concerning the authorisation of a preparation of endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142) as a feed additive for chickens for fattening, minor poultry species for fattening and weaned piglets, and amending Regulations (EC) No 2148/2004 and (EC) No 1520/2007 (holder of authorisation Huvepharma NV)
o izdaji dovoljenja za pripravek iz endo-1,4-beta-glukanaze (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142), kot krmni dodatek za piščance za pitanje, manjše vrste perutnine za pitanje in odstavljene pujske ter o spremembi uredb (ES) št. 2148/2004 in (ES) št. 1520/2007 (imetnik dovoljenja je Huvepharma NV)
The preparation of endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142) (formerly Trichoderma longibrachiatum) hereinafter referred to as ‘the preparation specified in the Annex’ was authorised without a time limit in accordance with Directive 70/524/EEC as a feed additive for chickens for fattening by Commission Regulation (EC) No 2148/2004 [3] and for weaned piglets by Commission Regulation (EC) No 1520/2007 [4].
Pripravek iz endo-1,4-beta-glukanaze (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142) (prej Trichoderma longibrachiatum) (v nadaljnjem besedilu: pripravek iz Priloge), je bil v skladu z Direktivo 70/524/EGS brez časovne omejitve odobren kot krmni dodatek za piščance za pitanje z Uredbo Komisije (ES) št. 2148/2004 [3], za odstavljene pujske pa z Uredbo Komisije (ES) št. 1520/2007 [4].
In accordance with Article 10(2) of Regulation (EC) No 1831/2003 in conjunction with Article 7 of that Regulation, an application was submitted for the re-evaluation of the preparation of endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142) (formerly Trichoderma longibrachiatum) as a feed additive for chickens for fattening, minor poultry species for fattening and weaned piglets.
V skladu s členom 10(2) Uredbe (ES) št. 1831/2003 v povezavi s členom 7 navedene uredbe je bil predložen zahtevek za ponovno oceno pripravka iz endo-1,4-beta-glukanaze (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142) (prej Trichoderma longibrachiatum), kot krmnega dodatka za piščance za pitanje, manjše vrste perutnine za pitanje in odstavljene pujske.
The European Food Safety Authority (‘the Authority’) concluded in its opinions of 17 April 2013 [5] and 10 March 2015 [6] that, under the proposed conditions of use, the preparation of endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142) (formerly Trichoderma longibrachiatum) does not have an adverse effect on animal health, human health or the environment.
Evropska agencija za varnost hrane (v nadaljnjem besedilu: Agencija) je v mnenjih z dne 17. aprila 2013 [5] in 10. marca 2015 [6] ugotovila, da pripravek iz endo-1,4-beta-glukanaze (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142) (prej Trichoderma longibrachiatum), pod predlaganimi pogoji uporabe nima škodljivega učinka na zdravje živali in ljudi ali na okolje.
The Authority also concluded that the use of that preparation has the potential to be efficacious in chickens for fattening and weaned piglets.
Poleg tega je Agencija ugotovila, da je lahko uporaba navedenega pripravka učinkovita pri piščancih za pitanje in odstavljenih pujskih.
The Authority further considered that the conclusions on the efficacy can be extrapolated to minor poultry species for fattening.
Agencija je nadalje menila, da se ugotovitve o učinkovitosti lahko ekstrapolirajo na manjše vrste perutnine za pitanje.
The assessment of the preparation of endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142) (formerly Trichoderma longibrachiatum) shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied.
Ocena pripravka iz endo-1,4-beta-glukanaze (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142) (prej Trichoderma longibrachiatum), je pokazala, da so pogoji za dovoljenje iz člena 5 Uredbe (ES) št. 1831/2003 izpolnjeni.
Accordingly, the use of that preparation should be authorised as specified in the Annex to this Regulation.
Zato bi bilo treba dovoliti uporabo navedenega pripravka, kakor je določeno v Prilogi k tej uredbi.
Regulations (EC) No 2148/2004 and (EC) No 1520/2007 should be amended accordingly.
Uredbi (ES) št. 2148/2004 in (ES) št. 1520/2007 bi bilo treba ustrezno spremeniti.
In Annex IV to Regulation (EC) No 2148/2004 the entry on E 1616, endo-1,4-beta-glucanase, is deleted.
V Prilogi IV k Uredbi (ES) št. 2148/2004 se črta vnos za E 1616, endo-1,4-beta-glukanazo.
Amendment to Regulation (EC) No 1520/2007
Sprememba Uredbe (ES) št. 1520/2007
Annex V is deleted.
priloga V se črta.
The preparation specified in the Annex, and feed containing that preparation, which is produced and labelled before 30 June 2016 in accordance with the rules applicable before 31 December 2015 may continue to be placed on the market and used until the existing stocks are exhausted.
Pripravek iz Priloge in krma, ki vsebuje navedeni pripravek, proizvedena in označena pred 30. junijem 2016 v skladu s pravili, ki se uporabljajo pred 31. decembrom 2015, se lahko še naprej dajeta na trg in uporabljata do porabe obstoječih zalog.
Commission Regulation (EC) No 1520/2007 of 19 December 2007 concerning the permanent authorisations of certain additives in feedingstuffs (OJ L 335, 20.12.2007, p. 17).
Uredba Komisije (ES) št. 1520/2007 z dne 19. decembra 2007 o trajnem dovoljenju nekaterih dodatkov v krmi (UL L 335, 20.12.2007, str. 17).
EFSA Journal 2013; 11(7):3207.
EFSA Journal (2013);11(7):3207.
EFSA Journal 2015; 13(3):4054.
EFSA Journal (2015);13(3):4054.
Functional group: digestibility enhancers.
Funkcionalna skupina: pospeševalci prebavljivosti
Additive composition:
Pripravek iz endo-1,4-beta-glukanaze (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142), z najmanjšo aktivnostjo 2000 CU [1]/g (v trdni in tekoči obliki).
Preparation of endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142) with a minimum activity of 2000 CU [1]/g (solid and liquid form).
Lastnosti aktivne snovi
Characterisation of the active substance:
Endo-1,4-beta-glukanaza (EC 3.2.1.4), ki jo proizvaja Trichoderma citrinoviride Bisset (IM SD142).
Endo-1,4-beta-glucanase (EC 3.2.1.4) produced by Trichoderma citrinoviride Bisset (IM SD142).
Analitska metoda [2]Za določanje endo-1,4-beta-glukanaze v krmnih dodatkih, premiksih in krmi: